Sebastian Gensior

European biopharma companies frequently monetize their U.S. royalty streams by selling them to American investors. In theory, these royalty financing rights could be sold to European investment funds — yet in practice this remains uncommon.

The first full week of 2026 delivered an unusually dense news cycle. Billion-dollar acquisitions, major licensing partnerships, the year's first biotech IPO, and the FDA's sweeping deregulation of wellness AI at CES 2026 combined to produce one of the more new dense weeks.

A comprehensive analysis of AI-powered healthcare innovations, regulatory shifts, strategic partnerships, and emerging technologies reshaping medicine and wellness

CPP Investments has deployed over $4 billion in life sciences since 2017—from Keytruda royalties to BridgeBio synthetics to biotech venture. How Canada's largest pension fund built a pharma powerhouse through patient capital and creative deal structures.

Introduction and Company Overview Founded in 1998, Gan & Lee Pharmaceuticals (SHSE: 603087) is a Chinese biopharma company specializing in insulin analogues and related medical devices. Headquartered in Beijing with an industrial park of ~200,000 m², Gan & Lee has grown to over 5,500 employees globally. The company

Taiwan's biotech industry reached record output in 2025 as the island leverages semiconductor-era manufacturing expertise to build Asia's next pharmaceutical hub. This analysis examines the companies, regulatory frameworks, CDMO expansion, and investment ecosystem shaping the sector's trajectory.

Pharmaceutical mergers and acquisitions face unprecedented antitrust scrutiny in the United States and European Union. Regulators no longer focus solely on obvious horizontal overlaps where merging firms sell competing drugs but also examine vertical foreclosure risks and pipeline competition—overlaps between marketed drugs and another company's pipeline candidates,

Clinical trial liability insurance represents a critical but often underestimated cost in drug development. The global clinical trials market reached approximately $76.7–87 billion in 2024 and is projected to grow at 5.2–6.3% CAGR through 2034, driving parallel expansion in the insurance sector. Understanding the complex

Biotech deal activity surges in year-end 2025 window The final week of 2025 and opening days of 2026 delivered over $15 billion in announced and closed transactions across the biotech and healthcare spectrum. Royalty Pharma completed its $300 million acquisition of remaining Evrysdi royalties on December 29, while several major

Sublicense royalties have become an important feature in pharmaceutical royalty financing deals, especially as biotech firms and pharma companies seek creative funding structures. In simple terms, a sublicense royalty (or sublicensing income) is the share of revenue that an original licensor earns when its licensee grants a sub-license to a